Search

Your search keyword '"Ruiz, Fabrice"' showing total 10 results
Start Over Author "Ruiz, Fabrice" Journal pharmaceutics
10 results on '"Ruiz, Fabrice"'

4. Exploring Acceptability Drivers of Oral Antibiotics in Children: Findings from an International Observational Study

Author

Vallet, Thibault, primary, Bensouda, Yahya, additional, Saito, Jumpei, additional, Mathiesen, Liv, additional, Pokharkar, Varsha, additional, Klingmann, Viviane, additional, Peak, Matthew, additional, Elhamdaoui, Omar, additional, Yamatani, Akimasa, additional, Ivanovic, Ivana, additional, Sajith, Manjusha, additional, Münch, Juliane, additional, Bracken, Louise, additional, Duncan, Jennifer Claire, additional, Salunke, Smita, additional, Wang, Siri, additional, and Ruiz, Fabrice, additional

Published
2021
Full Text
View/download PDF

9. Sex Differences in Medicine Acceptability: A New Factor to Be Considered in Medicine Formulation

Author

Ruiz, Fabrice, primary, Keeley, Alexander, additional, Léglise, Patrick, additional, Tuleu, Catherine, additional, Lachuer, Célia, additional, Rwabihama, Jean-Paul, additional, Bachalat, Nathalie, additional, Boulaich, Imad, additional, Abdallah, Fattima, additional, Rabus, Maité, additional, Ribemont, Annie-Claude, additional, Michelon, Hugues, additional, Wojcicki, Amélie Dufaÿ, additional, Orlu, Mine, additional, Vallet, Thibault, additional, and Boudy, Vincent, additional

Published
2019
Full Text
View/download PDF

10. Acceptability of Mebendazole Chewable Tablet in Children Aged 2 to 4 Years in Peru.

Author

Perez, Fernando, Vallet, Thibault, Bravo, Zarela, Callahan, Kristin, and Ruiz, Fabrice

Subjects
PARASITIC diseases, TREATMENT effectiveness, HELMINTHIASIS
Abstract

Soil-transmitted helminthiasis (STH) is among the most common of parasitic infections, affecting vulnerable populations in tropical/subtropical areas globally. In endemic countries, children, a high-risk population, require treatment and preventive interventions. Mebendazole, a WHO-recommended medicine, originally formulated as a tablet that was often crushed for administration to young children unable to swallow it, was reformulated as a chewable tablet. Acceptability is a key aspect for treatment effectiveness in pediatrics. Herein, we used a validated data-driven approach to investigate the acceptability of the 500-mg mebendazole chewable tablet in children aged 2 to 4 years in Peru. Observer-reported outcomes were collected for 182 medicine intakes. Acceptability was scored using the acceptability reference framework: a three-dimensional map juxtaposing "positively accepted" and "negatively accepted" profiles. Results found that the 500-mg mebendazole chewable tablet was classified as "positively accepted" in children aged 2 to 4 years. Acceptability increased with age and some acceptability issue remain for the younger children. Nevertheless, this formulation was considerably better accepted than the conventional tablets regardless of treatment in young children. This chewable formulation appears to be an appropriate alternative to the hard tablet of mebendazole for treatment of STH and preventive interventions in children aged 2 to 4 years. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results